

Amendments to the Claims:

No changes have been made to the claims. They are simply presented here for the convenience of the Examiner.

Listing of Claims:

1-32. (Cancelled)

33. (Previously Presented) A method of treating a CCX Chemokine Receptor (CCX CKR)-mediated condition in a mammal comprising administering to the mammal an agent that inhibits or promotes the binding of CCX CKR to ELC (EBI-1-ligand chemokine), SLC (secondary lymphoid organ chemokine), TECK (thymus expressed chemokine), BLC (B-lymphocyte chemoattractant), CTACK (cutaneous T cell attracting chemokine), mMIP-1 γ (murine macrophage inflammatory protein 1 γ), or vMIPII (viral macrophage inflammatory protein II) in a cell or tissue in the mammal, whereby inhibition or promotion of binding ameliorates the CCX CKR-mediated condition.

34. (Previously Presented) The method of claim 33, wherein the agent inhibits the binding of CCX CKR to ELC, SLC, TECK, BLC, CTACK, mMIP-1 γ or vMIPII.

35. (Previously Presented) The method of claim 33, wherein the CCX CKR-mediated condition is selected from the group consisting of inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an infectious disease and an immunosuppressive disease.

36. (Previously Presented) The method of claim 35, wherein the CCX CKR-mediated condition is inflammation.

37. (Previously Presented) The method of claim 33, wherein the agent promotes the binding of CCX CKR to ELC, SLC TECK, BLC, CTACK, mMIP-1 γ , or vMIPII.

38. (Withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is an allergic disease.

39. (Withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is an autoimmune disease.

40. (Withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is graft rejection.

41. (Withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is cancer.

42. (Withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is an infectious disease.

43. (Withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is an immunosuppressive disease.

44. (Previously Presented) The method of claim 33, wherein the mammal is a human.

45. (Previously Presented) The method of claim 33, wherein the mammal is a non-human primate.

46. (Previously Presented) The method of claim 33, wherein the agent is an antibody.

47. (Previously Presented) The method of claim 34, wherein the mammal is a human; and the CCX CKR-mediated condition is selected from the group consisting of inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an infectious disease or an immunosuppressive disease.

48. (Previously Presented) The method of claim 37, wherein
the mammal is a human; and
the CCX CKR-mediated condition is selected from the group consisting of
inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an infectious
disease or an immunosuppressive disease.